Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,695
Out of 5,140 analysts
8
Total ratings
11.11%
Success rate
-44.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $1.32 | +1,793.94% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $2.79 | +258.42% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $12.54 | -36.20% | 1 | Mar 11, 2024 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $32.75 | +156.49% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $11.78 | +239.56% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $8.74 | +25.86% | 1 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $1.00 | +2,000.84% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $900 | $6.14 | +14,569.93% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $1.32
Upside: +1,793.94%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $2.79
Upside: +258.42%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $12.54
Upside: -36.20%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $32.75
Upside: +156.49%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $11.78
Upside: +239.56%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $8.74
Upside: +25.86%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $1.00
Upside: +2,000.84%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $900
Current: $6.14
Upside: +14,569.93%